Internal Medicine, Hematology & Oncology · Columbia, SC
NPI
1932275336
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
166 Stoneridge Dr
Columbia, SC, 29210
Phone (803) 461-3000
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.0M
284,111 services
Medicare patients, 2024
1,106
Average age 75
Drug cost, 2024
$1.9M
1,006 prescriptions
Company payments, 2025
$1,877
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Scott R Sommers was code J1439 (injection, ferric carboxymaltose, 1 mg), 46,500 times for 50 patients. In total Scott R Sommers billed 284,111 services in 196 codes, and Medicare paid $5.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 46,500 | 50 | $0.87 | $40K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,400 | 35 | $44.72 | $868K |
| J0897 Injection, denosumab, 1 mg | Office | 17,220 | 67 | $20.40 | $351K |
| J9299 Injection, nivolumab, 1 mg | Office | 14,940 | 14 | $24.02 | $359K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 14,570 | 104 | $0.10 | $1,490 |
| J0185 Injection, aprepitant, 1 mg | Office | 13,650 | 41 | $1.34 | $18K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 10,260 | 13 | $38.99 | $400K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 9,700 | 40 | $4.40 | $43K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 7,128 | 36 | $21.28 | $152K |
| J9267 Injection, paclitaxel, 1 mg | Office | 5,680 | 11 | $0.08 | $445 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 5,650 | 11 | $2.33 | $13K |
| A9585 Injection, gadobutrol, 0.1 ml | Office | 3,720 | 27 | $0.24 | $892 |
| J9304 Injection, pemetrexed (pemfexy), 10 mg | Office | 3,535 | 11 | $45.90 | $162K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,667 | 79 | $0.09 | $239 |
| J9171 Injection, docetaxel, 1 mg | Office | 2,483 | 12 | $0.67 | $1,667 |
By year: 2022 $3.8M for 231,079 services; 2023 $4.4M for 269,156 services; 2024 $5.0M for 284,111 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,864 | 397 | $8.64 | $16K |
| 85025 Blood Count | 1,704 | 352 | $7.61 | $13K |
| 80048 Clinical Chemistry | 1,604 | 332 | $8.29 | $13K |
| 80076 Clinical Chemistry | 1,569 | 322 | $8.01 | $13K |
| 83615 Clinical Chemistry | 230 | 125 | $5.92 | $1,362 |
| 82728 Clinical Chemistry | 128 | 82 | $13.36 | $1,710 |
| 83550 Clinical Chemistry | 127 | 82 | $8.57 | $1,088 |
| 83540 Clinical Chemistry | 126 | 81 | $6.34 | $799 |
| 85044 Blood Count | 120 | 75 | $4.22 | $506 |
| 84153 Clinical Chemistry | 78 | 31 | $18.02 | $1,406 |
Medicare prescription drug claims, 2024
In 2024, the drug Scott R Sommers prescribed most often to Medicare patients was Letrozole, with 224 prescriptions and refills. In total Scott R Sommers wrote 1,006 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 224 | 538 | 93 | $6,819 |
| Prochlorperazine Maleate Generic | 102 | 102 | 63 | $1,055 |
| Tamoxifen Citrate Generic | 91 | 206 | 39 | $2,737 |
| Dexamethasone Generic | 55 | 78 | 31 | $1,144 |
| Acyclovir Generic | 50 | 75 | 16 | $725 |
| Hydroxyurea Generic | 35 | 80 | 14 | $1,278 |
| Potassium Chloride Generic | 34 | 42 | 19 | $447 |
| Oxycodone Hcl Generic | 30 | 30 | 19 | $335 |
| Ondansetron Odt Ondansetron | 24 | 26 | 15 | $481 |
| Prednisone Generic | 24 | 29 | 16 | $74.53 |
| Anastrozole Generic | 22 | 64 | 14 | $1,060 |
| Imatinib Mesylate Generic | 16 | 16 | Under 11 | $76K |
| Toremifene Citrate Generic | 15 | 15 | Under 11 | $13K |
| Imbruvica Ibrutinib | 14 | 14 | Under 11 | $219K |
| Exemestane Generic | 13 | 19 | Under 11 | $1,291 |
Brand drugs: 130 claims; generic drugs: 876 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Scott R Sommers $1,877 ($1,877 in general payments such as food, travel and fees) from 29 companies. The largest payer was Novartis Pharmaceuticals Corporation with $239.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 9 | $239 |
| Pfizer Inc. PFE | 11 | $199 |
| Janssen Biotech, Inc. JNJ | 6 | $123 |
| Merck Sharp & Dohme LLC MRK | 4 | $119 |
| Celgene Corporation BMY | 6 | $115 |
| Daiichi Sankyo Inc. 4568.T | 4 | $111 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $110 |
| Abbvie Inc. ABBV | 4 | $93.37 |
| Array Biopharma Inc PFE | 5 | $77.28 |
| Genentech USA, Inc. ROG.SW | 3 | $73 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.